New Vaccine Quality Assessment Assay Developed Using Conformation-Dependent Antibodies Coupled to SE-HPLC
Researchers have developed and validated a stability- and potency-indicating assay protocol for high-throughput quality assessment of vaccines consisting of recombinant virus- “like” particles (VLPs) using conformation-dependent antibodies coupled to size-exclusion high performance liquid chromatography (SE-HPLC).
Photo Credit: Kateryna Kon/Shutterstock.com
Researchers have developed and validated a stability- and potency-indicating assay protocol for high-throughput quality assessment of vaccines consisting of recombinant virus- “like” particles (VLPs) using conformation-dependent antibodies coupled to size-exclusion high performance liquid chromatography (SE-HPLC) (1).
Traditional vaccines utilizing attenuated or inactivated infectious agents often induce unpleasant side effects in their recipients, necessitating research into alternatives, and leading to the development of “subunit vaccines”. These vaccines do not contain live components of the pathogen, but instead contain recombinant protein antigens. Although cheaper to produce and safer to use than conventional vaccines, the recombinant proteins contained within these vaccines can suffer from poor immunogenicity and therefore require extensive testing to ensure effectiveness.
Subunit vaccines have been developed against viruses such as human papillomavirus (HPV), which is the most common cause of viral infections of the genital tract. Strains of HPV can be cancer causing, and have been found to be responsible for approximately 70% of cervical cancer and precancerous cervical lesions (2). The HPV vaccine is quadrivalent containing four types of non-infectious recombinant VLPs, however, currently ELISA remains the only approved in vitro potency testing assay for this vaccine. Despite good reproducibility and specificity, the protocol is time consuming, labour intensive, and sample volume demanding. These limitations raised the need for a more economic and industry friendly approach for quality assessment and batch release of HPV vaccine preparations.
Researchers developed an alternative method for vaccine evaluation using vacuum-immunoaffinity extraction (IAE) columns for sample preparation and IAE coupled to SE-HPLC for the determination of VLPs. The results were compared to the conventional ELISA assay and excellent specificity, sensitivity, and precision were found. The IAEâSEâHPLC assay protocol was demonstrated to be superior to ELISA, extensively reducing analysis time and cost.
References
- M.M. Mostafa et al., J. Chromatogr. B1032, 211–217 (2016).
- WHO fact sheet, Human Papillomavirus (HPV) and Cervical Cancer Fact SheetNo380, 2015 http://www.who.int/mediacentre/factsheets/fs380.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
